NASDAQ$AMLX

Amylyx Pharmaceuticals Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Headline financials

Total Revenue

$285K

No prior period
EPS (adj)

-$3.45

No prior period
Capital Expenditures

$153K

No prior period
Free Cash Flow

-$21M

No prior period
Net Income

-$23.1M

No prior period
Operating Income

-$22.9M

No prior period
Gross Profit

-$12.6M

No prior period
Stock-Based Comp

$802K

No prior period

Revenue & EPS history

Amylyx · Revenue · Quarterly

$285K

Q3 2021
Beat estimate in 3 of 8 quarters(38%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+0.3%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+7.4%

Avg return

30 days after

44%

8 / 18 earnings

Positive

+23.4%

Q4 2021

Best reaction

-30.7%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-7.6%-9.5%-2.3%
Q3 2025-5.9%-4.2%+7.3%
Q1 2025-6.0%-7.8%+9.4%
Q4 2024+0.3%+29.0%+17.0%
Q3 2024+7.7%+0.3%-17.4%
Q2 2024+1.1%+5.9%+26.1%
Q1 2024-8.8%-3.1%-8.3%
Q4 2023+15.3%+24.1%-82.1%
Q3 2023-30.7%-30.4%-22.2%
Q2 2023+0.5%-2.3%-4.5%
Q1 2023-4.4%-6.1%-11.9%
Q4 2022+11.2%-1.2%-3.9%
Q3 2022-1.8%+2.4%+3.0%
Q3 2021-1.8%+2.4%+3.0%
Q2 2021-5.5%-5.7%+12.7%
Q2 2022-5.5%-5.7%+12.7%
Q4 2021+23.4%+28.2%+97.5%
Q1 2022+23.4%+28.2%+97.5%
Q1 2021
Q4 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro